Raymond M. Jordt - 03 Jan 2023 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Business Officer
Signature
/s/ Richard I. Eisenstadt, as Attorney-in-Fact
Issuer symbol
ALT
Transactions as of
03 Jan 2023
Net transactions value
$0
Form type
4
Filing time
04 Jan 2023, 15:06:00 UTC
Next filing
02 Aug 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Stock Options (option to buy) Award $0 +125,000 $0.000000 125,000 03 Jan 2023 Common Stock, par value $0.0001 125,000 $15.63 Direct F1
transaction ALT Restricted Stock Units Award $0 +37,500 $0.000000 37,500 03 Jan 2023 Common Stock, par value $0.0001 37,500 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date.
F2 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F3 The RSUs become vested and exercisable over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.